BIOCHEMICAL MODULATION OF 5-FLUOROURACIL AND LEUCOVORIN IN COLORECTAL CANCER

5-氟尿嘧啶和亚叶酸在结直肠癌中的生化调节

• 批准号: 6122723
• 负责人: FREDERICK RICHARDS
• 金额: $ 3.88万
• 依托单位: WAKE FOREST UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122723
• 关键词: N phosphonoacetyl L aspartate; chemosensitizing agent; clinical research; clinical trial phase I; colorectal neoplasms; combination chemotherapy; drug resistance; drug screening /evaluation; fluorouracil; human subject; human therapy evaluation; leucovorin; neoplasm /cancer chemotherapy

The development or resistance to anti-cancer drugs is the principal cause of chemotherapy failure in cancer patients. The goal of this study is to increase the response to the anti-cancer agent 5-fluorouracil by overcoming tumor cell resistance with a second anti-cancer agent PALA. This study uses a 3X3 factorial design to assess the joint effects of PALA, leucovorin and fluorouracil on various biochemical endpoints in patients with resectable colorectal cancer. The results will provide a basis for improving therapy.

对抗癌药物的发展或耐药性是主要原因 癌症患者化疗失败的概率 本研究的目的是 提高对抗癌剂5-氟尿嘧啶的反应， 用第二抗癌剂PALA治疗肿瘤细胞抗性。 本研究 使用3X 3析因设计评估PALA、甲酰四氢叶酸 和氟尿嘧啶对各种生化终点的影响 可切除的结直肠癌 研究结果将为 改善治疗。